Physicians' Academy for Cardiovascular Education

GLP-1RAs: What are the future directions in development?

5 Things a cardiologist needs to know about GLP-1 RA

Subtitling in English, German, Italian, Spanish, French, and Chinese

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD - London, United Kingdom - Online CME

5 Things a cardiologist needs to know about GLP-1 RA Prof. Deanfield discusses the changing paradigm for managing cardiometabolic risk in clinical practice by the emergence of diabetes. He states that GLP-1 receptor agonists will be an important component of treatment strategies.

Video navigation menu

  • Obesity drives T2DM and CVD 00:35
  • How do GLP-1RAs reduce CV risk? 03:13
  • Strategies to prevent T2DM and CVD 06:21
  • Barriers to use of GLP-1RAs 09:32


Show transcript

Educational information

This educational video is part of a series called '5 Things a cardiologist needs to know about GLP-1 RA' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand why GLP-1 RAs are promising as multifactorial treatment for patients with T2D and/or obesity and CVD, and to improve clinical implementation of guidelines recommending treatment with anti-diabetic drugs with CV benefit.


Prof. John Deanfield, Professor of Cardiology, University College London, United Kingdom.


This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.

Podcast of this presentation


This is available as accredited online CME for members. Click the button below to enroll:

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: